CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans
1. CVS declines to add Gilead's Yeztugo due to clinical and financial factors. 2. Yeztugo is the first twice-yearly HIV drug, priced over $28,000 annually. 3. CVS faces legal scrutiny with nearly $290 million in damages for Medicare overcharging. 4. Gilead projects significant insurer coverage for Yeztugo by 2025-2026. 5. CVS stock is down 0.23% amid ongoing regulatory challenges.